Valuation: Renalytix Plc

Market Cap 13.34M 11.55M 10.77M 9.9M 18.7M 1.27B 18.9M 127M 49.66M 634M 50.09M 48.98M 2.1B P/E 2024
-0.45x
P/E 2025 -1.34x
Enterprise Value 17.94M 15.53M 14.48M 13.32M 25.14M 1.71B 25.42M 170M 66.79M 853M 67.36M 65.88M 2.83B EV / Sales 2024
11,059,330x
EV / Sales 2025 12,499,418x
Free-Float
73.31%
Yield 2024 *
-
Yield 2025 -
1 day+10.25%
Current month+10.25%
3 months+9.94%
6 months-0.50%
Current year-48.61%
Current year 0.02
Extreme 0.0231
0.06
1 year 0.02
Extreme 0.0231
0.18
3 years 0.02
Extreme 0.0231
1.39
5 years 0.02
Extreme 0.0231
12.42
10 years 0.02
Extreme 0.0231
17.15
Manager TitleAgeSince
Chief Executive Officer 58 2018-03-14
Director of Finance/CFO 68 2024-05-27
President 65 2024-04-29
Director TitleAgeSince
Chairman 62 2024-11-04
Director/Board Member 58 2018-03-14
Chairman 74 -
Change 5-day change 1-year change 3-year change Capi.($)
+10.25%-0.28% - - 17.04M
+0.57%+2.92%+27.38%-37.12% 16.4B
-0.51%+4.36%+6.50%+114.13% 1.83B
-0.48%+6.03%-26.12%-79.15% 1.2B
-0.22%-0.44%-34.37%+22.50% 984M
-0.98%+4.12%-45.91%-52.09% 668M
-2.01%+3.27%-47.59%-52.01% 547M
+0.16%+13.15%+78.02%-45.44% 521M
-0.16%+3.23%-50.19%-46.62% 393M
-0.40%+2.63%-12.93%-28.06% 372M
Average +0.67%+3.78%-11.69%-22.65% 2.55B
Weighted average by Cap. +0.22%+2.95%+15.50%-25.64%

Financials

2024 2025
Net sales 2.29 1.98 1.85 1.7 3.21 217.65 3.24 21.72 8.52 108.9 8.6 8.41 360.68 3 2.6 2.42 2.23 4.21 285.26 4.25 28.46 11.17 142.73 11.27 11.02 472.71
Net income -33.46M -28.98M -27.01M -24.84M -46.9M -3.18B -47.42M -317M -125M -1.59B -126M -123M -5.27B -20.4M -17.67M -16.47M -15.15M -28.6M -1.94B -28.92M -194M -75.96M -971M -76.62M -74.93M -3.21B
Net Debt 3.86M 3.34M 3.11M 2.86M 5.4M 367M 5.46M 36.57M 14.35M 183M 14.48M 14.16M 607M 4.6M 3.98M 3.71M 3.42M 6.45M 437M 6.52M 43.64M 17.13M 219M 17.28M 16.9M 725M
Logo Renalytix Plc
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. KidneyIntelX, is a vitro diagnostic platform, employs a proprietary algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record or EHR, systems, to generate a patient risk score. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Employees
46
Date Price Change Volume
26-08-05 US$0.0398 +10.25% 10,000

Annual profits - Rate of surprise